LB Pharmaceuticals LBRX 深 沪
等待开盘 08-11 09:30:00 美东时间
45.85
-2.150
-4.48%
华盛通- 最 高48.94
- 今 开47.68
- 成交量 42.59万股
- 最 低 43.91
- 昨 收 48.00
- 总市值 13.15亿
- 52周最高 49.14
- 市盈率 静 --
- 换手率 1.49%
- 52周最低 13.36
- 委 比 25.09%
- 总股本 2867.67万
- 历史最高 49.14
- 量 比 0.86
- 振 幅 10.48%
- 历史最低 13.36
- 每 手 1
- 风险率 7.01%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
HC Wainwright & Co. Reiterates Buy on LB Pharmaceuticals, Maintains $45 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates LB Pharmaceuticals (NASDAQ:LBRX) with a Buy and maintains $45 price target.
08-03 18:33
LB Pharmaceuticals launches $150M private placement
LB Pharmaceuticals (LBRX) has entered into a securities purchase agreement to sell 3.58M shares of its common stock and pre-funded warrants to purchase up to 715,513 shares of its common stock in a pr...
07-29 20:52
LB Pharmaceuticals Commences ~$150M Offering Of Common Shares, Pre-Funded Warrants
LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain diseases, today announced that it has entered into a securities purchase...
07-29 20:02
LB Pharmaceuticals Announces $150 Million Private Placement
LB Pharmaceuticals announced a private placement of 3.577 million shares and pre-funded warrants, raising approximately $150 million to expand its pipeline for LB-102, targeting schizophrenia and Alzheimer's disease. The financing involved several institutional investors, with Leerink Partners and Piper Sandler as placement agents. LB-102, a novel antipsychotic, has shown promising results in Phase 2 trials for schizophrenia and is being tested i...
07-29 12:00
美股牛股 | 超微电脑劲升19%，Q2毛利率大幅跃升，积压订单创新高；制药公司ARWR升逾19%
云计算公司QMLS飙升34%，获批英伟达合作伙伴资质；超微电脑劲升19%，Q2毛利率大幅跃升，积压订单创新高；制药公司ARWR升逾19%，甘油三酯药物试验成功积极>>
07-23 15:25
LB Pharmaceuticals accelerates Phase 3 schizophrenia trial timeline
LB Pharmaceuticals, Inc. ( ($LBRX) ) just unveiled an announcement. On July 22,...
07-22 20:54
美股大行评级 | 富国银行上调亚马逊目标价从313美元升至322美元；潜在涨幅370.99%！HC Wainwright上调Greenwich LifeSciences目标价至69美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从50美元升至69美元；高盛：维持Taysha Gene Therapies"买入"评级，目标价从11美元升至13美元
07-22 11:35
BMO Capital Initiates Coverage On LB Pharmaceuticals with Outperform Rating, Announces Price Target of $46
BMO Capital analyst Malcolm Hoffman initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Outperform rating and announces Price Target of $46.
07-21 17:34
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
LB Pharmaceuticals granted Christopher Zergebel, its new Senior Vice President of Clinical Operations, an equity award under the 2025 Equity Incentive Plan. The award includes an option to purchase 75,000 shares with a $32.95 exercise price, vesting over four years. LB-102, the company's lead candidate, is a novel benzamide antipsychotic for neuropsychiatric disorders. It showed promising results in a Phase 2 trial for acute schizophrenia, with s...
07-10 20:38
